CN114469974A - Application of astragaloside in preparation of medicine for preventing Alzheimer's disease - Google Patents
Application of astragaloside in preparation of medicine for preventing Alzheimer's disease Download PDFInfo
- Publication number
- CN114469974A CN114469974A CN202210011851.0A CN202210011851A CN114469974A CN 114469974 A CN114469974 A CN 114469974A CN 202210011851 A CN202210011851 A CN 202210011851A CN 114469974 A CN114469974 A CN 114469974A
- Authority
- CN
- China
- Prior art keywords
- astragaloside
- disease
- preventing alzheimer
- astragalosides
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 title claims abstract description 50
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 230000014509 gene expression Effects 0.000 claims abstract description 12
- 108010033040 Histones Proteins 0.000 claims abstract description 10
- 230000006607 hypermethylation Effects 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 4
- 241001061264 Astragalus Species 0.000 claims description 19
- 235000006533 astragalus Nutrition 0.000 claims description 18
- 210000004233 talus Anatomy 0.000 claims description 18
- 230000019491 signal transduction Effects 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007514 neuronal growth Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 16
- 239000012528 membrane Substances 0.000 description 15
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 14
- 229930182490 saponin Natural products 0.000 description 14
- 150000007949 saponins Chemical class 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical group Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 210000002243 primary neuron Anatomy 0.000 description 8
- 239000003292 glue Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002033 PVDF binder Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 229960004640 memantine Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 3
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 3
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 3
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 3
- 102000034570 NR1 subfamily Human genes 0.000 description 3
- 108020001305 NR1 subfamily Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- MASUWVVNWALEEM-UHFFFAOYSA-M 1-methoxy-5-methylphenazin-5-ium;methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2N=C3C(OC)=CC=CC3=[N+](C)C2=C1 MASUWVVNWALEEM-UHFFFAOYSA-M 0.000 description 1
- -1 2-Methoxy-4-nitrophenyl Chemical group 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091006149 Electron carriers Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- CKNCMXJRFAUMEO-UHFFFAOYSA-N S(=O)(=O)(OC)OC.COC1=CC=CC2=[N+](C3=CC=CC=C3N=C12)C Chemical compound S(=O)(=O)(OC)OC.COC1=CC=CC2=[N+](C3=CC=CC=C3N=C12)C CKNCMXJRFAUMEO-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229960000967 memantine hydrochloride Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Steroid Compounds (AREA)
Abstract
The invention provides application of astragalosides in preparation of a medicament for preventing Alzheimer's disease, wherein the astragalosides can be astragalosides, available salts of the astragalosides, solvates of the astragalosides or astragaloside derivatives. The astragaloside can promote the growth of neurons, improve the expression quantity of NMDAR-CREB signal path related protein, inhibit histone hypermethylation, relieve cognitive dysfunction and realize the effect of preventing Alzheimer's disease.
Description
Technical Field
The invention relates to the field of biological medicines, in particular to application of astragaloside in preparing a medicine for preventing Alzheimer's disease.
Background
Alzheimer's Disease (AD), a progressive neurodegenerative disease. Epigenetic disorders, which result in alterations in gene expression in the brain, are considered to be one of the key pathophysiological bases of alzheimer's disease. In a mouse model of late Familial Alzheimer Disease (FAD), the inhibitory histone H3 dimethylation of lysine 9(H3K9me2) is significantly increased, which is related to the reduction of transcription, expression and function of NMDA receptors, and finally leads to clinical features such as cognitive function impairment and learning and memory impairment. With the aggravation of the aging degree of China, AD becomes an extremely powerful effect on the health of the old. Effective prevention and treatment of AD has become important. The natural micromolecules in the traditional Chinese medicine and the natural compounds have the characteristics of small molecular weight, easy synthesis, administration and the like, and have wide prospects in the field of prevention and treatment of Alzheimer's disease.
Astragalosides are natural active substances with various pharmacological effects, and have attracted general attention of the international society. Tests and clinical application prove that the astragaloside regulates the immune function of an organism, and has the functions of promoting cell proliferation, improving cell metabolism and the like. In recent years, people find that the natural plant astragalus contains a large amount of astragalus saponin, and the astragalus is a traditional Chinese medicine and has a wide source, so that great progress is made in extracting the astragalus saponin from the astragalus.
The astragalosides are natural saponin components separated and purified from traditional Chinese medicine radix astragali, and have various pharmacological effects. However, whether astragalosides can be natural drugs for preventing alzheimer's disease has not been sufficiently studied.
Disclosure of Invention
In order to solve the technical problems, the invention provides the application of the astragaloside in the preparation of the medicine for preventing the alzheimer disease, finds that the astragaloside can inhibit the hypermethylation of histone, relieve the cognitive dysfunction and realize the effect of preventing the alzheimer disease, provides a brand new thought for preventing the alzheimer disease at present, widens the selection field for treating the alzheimer disease and also makes a contribution to the further development of the astragaloside.
The technical scheme of the invention is as follows:
the invention provides application of astragaloside, an available salt of astragaloside, a solvate of astragaloside or an astragaloside derivative in preparation of a medicament for preventing Alzheimer's disease.
As a preferred embodiment of the invention, the astragaloside is prepared by separating and purifying traditional Chinese medicine astragalus.
As a preferred embodiment of the present invention, the astragaloside is provided in the form of a plant extract.
As a preferred embodiment of the present invention, the astragaloside further comprises an optional pharmaceutically acceptable carrier and/or excipient.
As a preferred embodiment of the present invention, the astragalosides can promote the growth of neurons.
In a preferred embodiment of the present invention, the astragalosides can inhibit histone hypermethylation, resolve cognitive dysfunction, and achieve an effect of preventing alzheimer's disease.
As a preferred embodiment of the invention, the astragaloside can improve the expression level of the protein related to the NMDAR-CREB signaling pathway.
The invention provides a medicine for preventing Alzheimer's disease, which comprises at least one of astragalus saponin, an available salt of the astragalus saponin, a solvate of the astragalus saponin or an astragalus saponin derivative.
The invention provides a pharmaceutical composition for preventing Alzheimer's disease, which comprises the medicine for preventing Alzheimer's disease.
Compared with the prior art, the invention has the following beneficial effects:
the astragaloside promotes the growth of neurons, inhibits the hypermethylation of histone in Alzheimer's disease, improves the expression quantity of NMDAR-CREB signal pathway related protein, provides a brand new thought for preventing Alzheimer's disease at present, widens the selection field for treating Alzheimer's disease, and makes contribution to the further development of astragaloside.
Drawings
FIG. 1 shows the result of the absorbance at 450nm of C, D, A β, AS group neurons;
FIG. 2 shows the result of H3K9me2 methylation immunofluorescence staining of C, D, A beta, AS, and Memantine group neurons;
FIG. 3 shows the result of the expression level of NMDAR-CREB signaling pathway protein of C, D, A beta, AS and Memantine group neurons.
Detailed Description
The present invention will be described in detail below with reference to the accompanying drawings.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The cells used in the following examples were primary neurons obtained from SD rat suckling mice (purchased from the university of Lanzhou laboratory animal center) and cultured in neurobasal (neurobasal-A) (1X) medium supplemented with B27 and glutamine. Neurons of div.14 were dosed for subsequent experiments.
The reagents relevant to the examples were prepared as follows:
preparation of Abeta oligomers
1mg of Abeta1-42Dissolving powder (Anaspec) with 222 μ L precooled hexafluoroisopropanol (HFIP, sigma), shaking, mixing, standing at room temperature for 60min, standing on ice for 10min to obtain 1mmoL/L of A β1-42And (3) solution. The evaporated HFIP was dried under vacuum until a clear A.beta.was produced at the bottom of the EP tube1-42-HFIP-peptide membranes, long-term storage at-80 ℃. When in use, the peptide membrane is taken out, 44 mu L DMSO is added and mixed well to prepare 5mM Abeta1-42And (4) mother liquor. Adding 2156 μ L of precooled PBS to obtain 100 μmoL/L of Abeta1-42And (4) working fluid. Incubating at 4 deg.C for 24h, centrifuging at 4 deg.C/14000 x g for 10min, removing precipitate, sucking supernatant, and filtering with filter to obtain Abeta1-42Oligomers, stored in aliquots at-80 ℃.
2. Memantine configuration
Memantine hydrochloride (sigma) 10mg was dissolved in 10mL ddH2And O, fully dissolving, filtering by a filter, and storing at 4 ℃.
2. Astragalus saponin solution
The astragaloside solution is obtained by laboratory extraction.
Example 1
cck8 detection of Primary neuron Activity
The CCK-8 reagent (Cell Counting Kit-8 Cell Counting reagent) contains WST-8, the chemical name of which is 2- (2-Methoxy-4-nitrophenyl) -3- (4-nitrophenyl) -5- (2, 4-disulfonic acid benzene) -2H-tetrazole monosodium salt, which is reduced into a yellow Formazan product (Formazan) with high water solubility by dehydrogenase in Cell mitochondria under the action of an electron carrier 1-Methoxy-5-methylphenazinium dimethyl sulfate (1-Methoxy PMS), and the number of the generated Formazan product is in direct proportion to the number of living cells. The light absorption value of the enzyme linked immunosorbent assay device is measured at the wavelength of 450nm, and the quantity of living cells can be indirectly reflected. The method is widely used for activity detection of some bioactive factors, large-scale screening of anti-tumor drugs, cell proliferation tests, cytotoxicity tests, drug sensitivity tests and the like.
Test materials: 3d SD rat (purchased from Lanzhou university laboratory animal center), CCK-8 kit, sheep serum, PBS, fetal bovine serum, horse serum, B27 culture medium, penicillin and streptomycin, and astragaloside.
The specific experimental steps are as follows:
dividing primary neurons into 4 groups, respectively recording AS C, D, A beta and AS, respectively inoculating the groups into a 96-well plate, and when cells grow to the density of 70% -80%, and fully adhering to the wall, carrying out no treatment on the group C; group D was treated with DMSO: PBS 1:49 solvent; adding Abeta to Abeta group1-42Oligomer treatment; the AS group is treated by 50ug/ml of astragalus saponin solution, cultured for 2 hours after adding medicine, and then added with Abeta1-42The oligomers were incubated for 24 hours.
After the treatment time is over, cck8 incubation liquid is prepared according to the instructions of a cck8 kit, 4 groups of 96-well plates are added in equal amount for incubation for 2 hours, and the absorbance at 450nm is detected by using an enzyme-labeling instrument, as shown in figure 1.
As can be seen from FIG. 1, A.beta.1-42Oligomers induced a decrease in the viability of primary neurons, and astragalosides reversed this trend.
Example 2
Immunofluorescence staining
Immunofluorescence technology (Immunofluorescence technology) is a technology established on the basis of immunological, biochemical and microscopic techniques. This technique utilizes an antigen-antibody reaction to localize an antigen substance in a tissue or a cell.
Test materials: 3d SD rat (purchased from Lanzhou university laboratory animal center), Anti-MAP2antibody, 488 fluorescent antibody, sheep serum, PBS, fetal bovine serum, horse serum, B27 culture medium, penicillin and streptomycin, and astragaloside.
The specific experimental steps are as follows:
dividing primary neurons into 5 groups, respectively recording AS C, D, A beta, AS and Memantine, respectively inoculating on a glass slide in a 24-well plate coated with polylysine, respectively, allowing cells to grow to 70% -80% in density, and allowing group C to be completely adherent without any treatment; group D was treated with DMSO: PBS 1:49 solvent; adding Abeta to Abeta group1-42Oligomer treatment; the AS group is treated by 50ug/ml of astragalus saponin solution, cultured for 2 hours after adding medicine, and then added with Abeta1-42Oligomers were incubated for 24 hours; memantine group was treated with 5ug/ml Memantine, cultured for 2 hours after adding drug, and then Abeta was added1-42The oligomers were incubated for 24 hours.
After the treatment time was over, 5 groups of the culture medium were aspirated, and the cells were fixed with 2% paraformaldehyde solution for 15min at room temperature. Washing with PBS for 5min x 3 times; adding goat serum, sealing for 1h, washing with PBS for 5min x 3 times; incubating with anti-H3K 9me2 primary antibody at 4 degrees overnight; on the next day, the primary antibody is aspirated off, washed with PBS for 5min x 3 times, incubated with Alexa Fluor-FITC secondary antibody at room temperature in the dark for 2h, washed with PBS for 5min x 3 times, DAPI counterstained for 10min, washed with PBS for 5min x 3 times, spotted with a drop of blocking tablet on the slide, then the round cover fragment is taken out to flip the cell surface onto the slide, and the slide is placed in a wet box in the dark for storage at 4 ℃ for convenient subsequent photographing. The antibodies used in this example include: anti-H3K 9me2(Abcam, 1: 200); alexa Fluor-FITC secondary antibody (Abcam, 1:100), DAPI (sigma, 1: 10000). Changes in fluorescence intensity were captured with a Zeiss inverted fluorescence microscope at 10, 20, and 40 Xmagnification, respectively, and the results are shown in FIG. 2.
As can be seen from FIG. 2, astragaloside inhibits histone hypermethylation, and the action effect is similar to that of memantine which is a marketed drug for treating Alzheimer's disease.
Example 3
Western-blot detection of change of expression level of NMDAR-CREB (N-methylglucamine-polymerase chain reaction) -signal pathway
Western Blot (immunoblot assay) is used. It is a commonly used experimental method in molecular biology, biochemistry and immunogenetics. The basic principle is to stain a gel electrophoresis-treated cell or biological tissue sample with a specific antibody. Information on the expression of a specific protein in the analyzed cell or tissue is obtained by analyzing the location and depth of staining. The NMDAR-CREB signaling pathway related proteins are NR2B, NR1, NR2A and CREB.
Test materials: primary neurons cultured from the cortex of the brain tissue and hippocampus of SD suckling mice, sheep serum, PBS, fetal bovine serum, horse serum, DMEM medium (Gibco), penicillin and streptomycin, astragaloside, PMSF, isopropanol, RIPA, and skim milk powder.
The specific experimental steps are as follows:
dividing primary neurons into 5 groups, respectively recording AS C, D, A beta, AS and Memantine, respectively inoculating the groups into a 6-well plate, and when cells grow to 70% -80% density and adhere to the wall completely, performing no treatment on the group C; group D was treated with DMSO: PBS 1:49 solvent; adding Abeta to Abeta group1-42Oligomer treatment; the AS group is treated by 50ug/ml of astragalus saponin solution, cultured for 2 hours after adding medicine, and then added with Abeta1-42Oligomers were incubated for 24 hours; memantine group was treated with 5ug/ml Memantine, cultured for 2 hours after adding drug, and then Abeta was added1-42The oligomers were incubated for 24 hours.
After different treatments, total protein is extracted from cells collected from 5 groups of 6-hole plates respectively, Western-blot experiments are carried out on NMDAR-CREB signal channel related proteins NR2B, NR1, NR2A and CREB, and cell lysates are used for collecting protein samples to lyse adherent cells, suspension cells or tissue samples. The protein concentration of each protein sample was then determined. An appropriate amount of concentrated SDS-PAGE protein loading buffer was added to the collected protein samples.
Preparing glue: installing a cleaned glass plate, preparing separation glue, quickly injecting the separation glue into the glass plate, adding the separation glue to 2/3 parts of the glass plate, smoothly injecting absolute ethyl alcohol into the glass plate to seal the glue surface, standing for 40-60 min, pouring out the absolute ethyl alcohol in the plate, washing for 3-5 times with distilled water, and then sucking excess water along the edge of the glass plate with filter paper. And (3) placing the glass plate, preparing 5% of concentrated glue, filling the residual gaps of the glass plate with the concentrated glue, inserting a comb, discharging redundant bubbles, and standing for 40-60 min.
And (3) electrophoresis, namely filling the solidified gel into an electrophoresis device, putting the groove on the glass plate opposite to the groove, and clamping the electrophoresis groove to prevent electrophoresis liquid from leaking and prevent the strip running out from being uneven. Adding 1x electrophoresis buffer solution into an electrophoresis tank, pulling out a comb, adding 2 mu L rainbow Marker, adding a sample to be detected into the sample loading holes according to the protein amount of each hole, and supplementing the same sample loading amount into each sample loading hole by using the 1x protein sample loading buffer solution. And (5) performing constant voltage electrophoresis at 65V, and adjusting the voltage to 90V after the gel is separated and continuing electrophoresis.
And (3) membrane transferring, namely diluting the 10x membrane transferring solution into 1x (the 10x membrane transferring solution is methanol: distilled water is 1:2:7), placing the membrane transferring solution in a refrigerator for precooling at 4 ℃, marking the PVDF membrane, and then putting the PVDF membrane in methanol for activation. After SDS-PAGE electrophoresis is finished, cutting the needed gel, stacking the white board (+), the sponge, the 3 layers of filter paper, the PVDF membrane, the gel, the 3 layers of filter paper, the sponge and the blackboard (I) in sequence, closing the membrane transferring clamp, and soaking the whole process in the membrane transferring liquid to avoid bubbles. Putting the materials into a film transfer groove in the sequence of red to red and black to black. The film is rotated by a constant current of 200mA, the film rotating time is generally 120min, the whole process of film rotation is carried out in an ice-water mixture, and the influence of heat generation in the process of film rotation on an experiment is prevented.
Sealing, namely placing the PVDF membrane after membrane conversion into sealing liquid, preparing 5% skimmed milk, and sealing at room temperature for at least 1 h.
And (3) performing immune hybridization reaction, namely diluting penicillin by using prepared 5% skimmed milk powder according to the dilution ratio of 1:1000, putting the target protein strip with the right side facing upwards into the diluted primary antibody, and shaking the mixture overnight at 4 ℃. The incubated primary antibody PVDF membrane was placed in TBST and washed on a shaker for 8min 3 times. Diluting the secondary antibody with 5% skimmed milk powder at a ratio of 1:10000, placing the strip into the diluted secondary antibody, incubating at room temperature for 2h, taking out the strip, and washing on a shaking table for three times for 12min each time. Wherein the primary antibody is: NR2B (bs-0222R, Boossen), CREB (bsm-33196M, Boossen), NR1(bs-23343R, Boossen), NR2A (bs-3507R, Boossen); the secondary antibody is: rabbit antibody (RS002, immunological), mouse antibody (RS001, immunological); GAPDH (P02436, Solape) is used as internal reference.
And (3) exposing, namely opening a hypersensitivity chemiluminescence apparatus in advance to pre-cool, placing the PVDF membrane in the apparatus after the apparatus is pre-cooled to-25 ℃, taking the fact that no air bubbles exist, enabling the protein surface to face upwards, dropping ECL luminescence liquid near target protein (liquid A and liquid B are mixed according to the ratio of 1: 1), starting exposing, and storing pictures after the exposure is finished, wherein GAPDH is shown in figure 3.
As can be seen from FIG. 3, A β1-42After the oligomer stimulates primary neuron cells for 24 hours, the expression level of NMDAR-CREB signaling pathway related protein is obviously reduced, and the expression level of NMDAR-CREB receptor is obviously increased after astragalus saponin treatment.
According to the embodiments, after the astragalus saponin pretreatment is carried out on the in-vitro AD cell model, the astragalus saponin is found to reduce A beta1-42Oligomer-induced histone hypermethylation, and Western-blotting results show that astragaloside improves the reduction of the expression level of NMDAR-CREB signaling pathway-related proteins caused by histone hypermethylation. Therefore, the astragalus saponin can be developed as a new medicament for preventing AD, and a new means and way are provided for inhibiting histone hypermethylation caused by AD.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (9)
1. Use of astragaloside, an acceptable salt of astragaloside, a solvate of astragaloside or an astragaloside derivative in the preparation of a medicament for preventing Alzheimer's disease.
2. The use of claim 1, wherein the astragaloside is obtained by separating and purifying a traditional Chinese medicine astragalus.
3. Use according to claim 1, wherein the astragaloside is provided in the form of a plant extract.
4. The use according to claim 1, wherein the astragaloside further comprises an optional pharmaceutically acceptable carrier and/or excipient.
5. The use as claimed in claim 1, wherein the astragaloside is capable of promoting neuronal growth.
6. The use as claimed in claim 1, wherein the astragaloside can inhibit histone hypermethylation, relieve cognitive dysfunction and realize the effect of preventing Alzheimer's disease.
7. The use according to claim 1, wherein the astragaloside is capable of increasing the expression level of an NMDAR-CREB signaling pathway related protein.
8. A medicine for preventing Alzheimer's disease is characterized by comprising at least one of astragaloside, an acceptable salt of astragaloside, a solvate of astragaloside or an astragaloside derivative.
9. A pharmaceutical composition for preventing Alzheimer's disease, which comprises the agent for preventing Alzheimer's disease according to claim 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210011851.0A CN114469974A (en) | 2022-01-06 | 2022-01-06 | Application of astragaloside in preparation of medicine for preventing Alzheimer's disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210011851.0A CN114469974A (en) | 2022-01-06 | 2022-01-06 | Application of astragaloside in preparation of medicine for preventing Alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114469974A true CN114469974A (en) | 2022-05-13 |
Family
ID=81510383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210011851.0A Pending CN114469974A (en) | 2022-01-06 | 2022-01-06 | Application of astragaloside in preparation of medicine for preventing Alzheimer's disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114469974A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389438A (en) * | 2011-06-30 | 2012-03-28 | 北京师范大学 | Application of Astragaloside IV |
| CN107281207A (en) * | 2016-03-30 | 2017-10-24 | 南京惠宝生物医药有限公司 | Astragaloside I is preparing the purposes in preventing and treating the medicine or health products of senile dementia |
| CN110974837A (en) * | 2019-12-19 | 2020-04-10 | 潘晓东 | Application of cycloastragenol in preparation of medicine for treating or preventing Alzheimer disease |
-
2022
- 2022-01-06 CN CN202210011851.0A patent/CN114469974A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389438A (en) * | 2011-06-30 | 2012-03-28 | 北京师范大学 | Application of Astragaloside IV |
| CN107281207A (en) * | 2016-03-30 | 2017-10-24 | 南京惠宝生物医药有限公司 | Astragaloside I is preparing the purposes in preventing and treating the medicine or health products of senile dementia |
| CN110974837A (en) * | 2019-12-19 | 2020-04-10 | 潘晓东 | Application of cycloastragenol in preparation of medicine for treating or preventing Alzheimer disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goslin et al. | The role of cytoskeleton in organizing growth cones: a microfilament-associated growth cone component depends upon microtubules for its localization. | |
| CN113603629B (en) | Cytochalasin compound with immunosuppressive activity and preparation method and application thereof | |
| Lai et al. | Allicin attenuates calcium oxalate crystal deposition in the rat kidney by regulating gap junction function | |
| Ishizuka et al. | A simple DMSO-based method for cryopreservation of primary hippocampal and cortical neurons | |
| US4241174A (en) | Interferon assay | |
| CN114469974A (en) | Application of astragaloside in preparation of medicine for preventing Alzheimer's disease | |
| CN111388651B (en) | Application of CST-14 in preparation of osteoporosis treatment medicine | |
| Cai et al. | Achyranthes bidentata polypeptide k enhances the survival, growth and axonal regeneration of spinal cord motor neurons in vitro | |
| CN108685906A (en) | The new opplication of micromolecular compound P7C3 | |
| CN109966476B (en) | Application of three components of scutellaria baicalensis to synergistic enhancement of FGF2 cell proliferation promotion | |
| CN113957053A (en) | Method for screening traditional Chinese medicine active ingredients of anti-intestinal cancer stem cells by using human intestinal cancer organoid | |
| Kim et al. | Exogenous CLASP2 protein treatment enhances wound healing in vitro and in vivo | |
| CN116036070B (en) | Application of 9' -salvianolic acid B monomethyl ester in preparation of medicines for treating breast cancer tumor cell proliferation, migration and invasion | |
| CN113304143B (en) | Application of hesperetin and/or derivatives thereof in preparation or application of hesperetin and/or derivatives thereof as anti-renal cancer drug sensitizer | |
| Azoulay-Alfaguter et al. | Isolation and characterization of T lymphocyte-exosomes using mass spectrometry | |
| CN113350331A (en) | Application of hesperetin and/or derivatives thereof in preparation of drugs or drugs for preventing and/or treating renal cell carcinoma | |
| UA76372C2 (en) | Method for producing cytological preparation of dendritic cells | |
| CN117805376B (en) | Application of CD44 and Lgr5 as markers in screening gastric cancer tumor stem cells | |
| CN111973612B (en) | Application of quercetin-3-O-beta-D-galactoside in preparation of medicament for promoting glucose absorption | |
| Chen et al. | Caco-2 cell monolayers as a model for studies of drug transport across human intestinal epithelium | |
| Kuo et al. | Decrease in Ca 2+-Activated K+ Conductance in Differentiated C6-Glioma Cells | |
| Kadota et al. | Effects of alkaloids from Corydalis decumbens on contraction and electrophysiology of cardiac myocytes | |
| CN115054592A (en) | Application of compound in preparation of medicine for treating proliferative hepatocellular carcinoma | |
| CN117737246A (en) | Application of PLCB1 gene as biomarker in invasive pituitary adenoma | |
| JP2024037109A (en) | Analysis container, pretreatment method, metabolite analysis method, protein analysis method, and mass spectrometry method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |